<DOC>
	<DOC>NCT00483132</DOC>
	<brief_summary>Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy. High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).</brief_summary>
	<brief_title>Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leuk√©mia(ALL) Adults Stage III</brief_title>
	<detailed_description>Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Criteria ALL high risk or low risk or lymphoblastic lymphoma age 1555 years old informed consent signed patients previously treated with a chemotherapy or alphainterferon ALL 3 (burkitt like)</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>